IPI-145 is an inhibitor of p110δ PI3K that exhibits anticancer chemotherapeutic, immunosuppressive, and anti-inflammatory activities. In clinical trials, IPI-145 displays potential benefit in the treatment of chronic lymphocytic leukemia (CLL). IPI-145 inhibits proliferation of B and T cells, inhibits neutrophil migration, and prevents basophil activation in vitro. It also induces apoptosis in CLL cells. In animal models of inflammatory diseases, IPI-145 decreases levels of matrix metalloproteinase 13 (MMP13) and IL-17, inhibiting Th17 T cell differentiation and decreasing arthritis severity and progression.